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Abstract
Introduction: The drug Licopid® (GMDP, glucosaminylmuramyldipeptide) is intended for complex therapy of con-
ditions accompanied by secondary immunodeficiencies. This drug belongs to the group of microbial immunomodu-
lators of bacterial origin. The transparent mechanism of action of the active substance GMDP allows putting the drug 
Licopid® into the category of promising immunotherapy drugs that are in demand in the complex therapy of many 
diseases resistant to traditional treatment. The objective of this study was to investigate the carcinogenicity of GMDP 
(Licopid®) in chronic animal experiments.
Materials and Methods: The study of the carcinogenic effects of GMDP was carried out in mice hybrids F1 CBAxC-
57BL6 and Wistar rats of both sexes with intragastric administration five days a week (Mon-Tue-Wed-Thu-Fri) for 18 
months at doses of 0.186 mg/kg, 1.86 mg/kg and 6.13 mg/kg to mice and for 21 months at doses of 0.086 mg/kg, 0.86 
mg/kg and 2.83 mg/kg to rats.
Results and Discussion: The results of the clinical observation of the experimental animals in the course of the study 
demonstrated the absence of differences between mice and rats of the experimental and control groups.
Conclusion: Intragastric administration of GMDP to male and female mice for 18 months and rats for 21 months at the 
studied doses did not lead to tumor formation in the experimental animals.
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Introduction
The drug Licopid® is intended for complex therapy of 
the states which are followed by secondary immuno-
deficiency. This drug belongs to the group of microbial 
immunomodulators of bacterial origin. The active agent 
of the drug Licopid® – glucosaminylmuramyldipeptide 
GMDP. It is the ancestor of this group of immunomo-
dulators and is an individual chemical compound, ob-
tained by semi-synthetic means. In its structure, GMDP 
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corresponds to the minimal repeating biologically active 
fragment of a peptidoglycan molecule that makes up the 
cell wall of all gram-positive and gram-negative bacte-
ria. GMDP and some of its structural derivatives, ob-
tained in both semi-synthetic and synthetic ways, have 
found medical application due to the discovery of their 
adjuvant, immunomodulatory, detoxifying and anti-tu-
mor properties, combined with pharmacological safety. 
In addition to GMDP, registered in the EEU countries 
under the trademark Licopid®, the following GMDP’s 
structural derivatives are registered: in Japan – Romur-
tid (trade name Nopia®); in the EU – Mifamurtid (trade 
name Mepact®); in the Ukraine – Liasten®. Preparations 
are under clinical study: in the EU – MTP-PE, DTP-GDP 
(ImmTher) and in Russia – GMDP-A (glucosaminylmu-
ramyldipeptide acid).
The specificity of GMDP and its derivatives is their 
ability to interact with the intracellular cytoplasmic recep-
tors of the innate immunity of the NOD family expressed 
in phagocytic cells and to activate the innate immunity in 
the same way as the bacteria themselves (Girardin et al. 
2003a, 2003b; Inohara et al. 2003). 
It was proven that for GMDP (Licopid®) the interac-
tion with the NOD2 receptor was absolutely specific and 
mediated the cellular and humoral adaptive immunity 
(Nesmeyanov 1998). A causal relationship was establis-
hed between the ability to bind to PRR-pattern-recogniti-
on receptors of the NOD2 family and the ability to induce 
a cascade of processes responsible for the activation of the 
transcription factor NF-kB and the subsequent stimulati-
on of immunity (Meshcheryakova et al. 2007). The belon-
ging of GMDP to NOD2 agonists expressed in phagocytic 
cells reveals in detail the mechanism of stimulating the 
functions of immunocompetent cells. Such transparency 
of the GMDP mechanism of action allows attributing the 
drug Licopid® to the category of promising immunothe-
rapy drugs that are in demand in the complex therapy of 
many diseases resistant to traditional treatment. 
Earlier, it was proved there were no gene mutations 
and chromosomal aberrations when exposed to GMDP. 
However, the affinity of the GMDP molecule for NOD2 
receptor molecules present not only in phagocytic cells, 
but also in other human cells and tissues, including some 
tumor myeloid lines (EMBL, EBI, ESTDAB, LSBM da-
tabases), served as the basis for a more detailed study of 
carcinogenic GMDP properties.
The objective of this study was to study the carcino-
genicity of GMDP (Licopid®) in chronic animal expe-
riments.
Materials and research methods
This study was conducted on the basis of the Research 
Institute of Pharmacology of Living Systems of Belgorod 
State National Research University to the order of Peptek 
JSC.
The conduct of this study was approved by the local 
ethical committee for working with laboratory animals.
The study of the carcinogenic effects of GMDP was 
carried out in mice hybrids F1 CBAxC57BL6 and Wistar 
rats of both sexes with intragastric administration five 
days a week (Mon-Tue-Wed-Thu-Fri) for 18 months at 
doses of 0.186 mg/kg, 1.86 mg/kg and 6.13 mg/kg to mice 
and for 21 months at doses of 0.086 mg/kg, 0.86 mg/kg 
and 2.83 mg/kg to rats (it had been originally planned to 
administer the drug to rats for 24 months, however, taking 
into account the dynamics of mortality, it was decided 
to discontinue the study in rats). The above doses were 
calculated using interspecies conversion of daily doses 
for humans of 1 mg and 10 mg, as well as a three-time 
maximum daily dose of 10 mg – 33 mg, which equaled 
after conversion the maximum permissible dose for mice 
and rats, according to the coefficients in (Freireich et al. 
1966). As the control, the data were used obtained from 
the intact animals (intragastric administration of an ap-
propriate volume of solvent). For research, healthy fema-
les and male mice and rats were used, 50 animals of each 
sex in the group. The distribution within the groups was 
in accordance with body weight, with variation not ex-
ceeding 10%. 
The animals were kept in standard conditions, in ac-
cordance with the approved Principles of good laborato-
ry practice. The cages were individually ventilated Tec-
niplast systems for small laboratory animals. Feed was 
rodent pellet diet. Access to the feed was free. Water was 
purified, sterilized by UV irradiation. Access to water 
was free, through Tecniplast drinkers. The environmental 
conditions were the following: air temperature – within 
20-26°C, relative humidity of air – within 30-70%; an ar-
tificial 12 h/12 h day/night cycle. Acclimatization and se-
lection of animals for the study – quarantine for at least 10 
days. Enrichment of the environment – Tecniplast mice 
houses.
The animals were monitored daily, recording the fol-
lowing information: their general condition, toxic events, 
deaths of animals, the occurrence of tumors. The animalas 
were weighed: during the first two months – weekly, du-
ring the 3rd and 4th months – twice a month, then – once 
a month. In the event of the death of the animal, comple-
te necropsy and macroscopic examination of the internal 
organs of the animal weer performed as soon as possible 
for the presence of a tumor. A routine necropsy was per-
formed on the bodies of mice and rats that had received 
the test drug for 18 and 21 months, respectively, and the 
organs and tissues were collected, followed by histologi-
cal examination. The euthanasia method was placement 
in a CO2 chamber.
The quantitative results were subjected to statistical 
processing by calculating the arithmetic mean (M), and 
standard error (±m). The intergroup differences were 
analyzed by parametric (Student’s t-test) methods. The 
differences were considered statistically significant with 
p<0.05. For statistical calculations, Microsoft Excel and 
Statistica 10.0 were used.
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Results and Discussion
The results of clinical observation of the experimental 
animals during the course of the study demonstrated the 
absence of differences between mice and rats of the expe-
rimental and control groups.
Thus, the general condition of the animals during the 
whole period of observation changed in accordance with 
age characteristics. No behavioral patterns were observed 
in the experimental animals different from those in the 
control animals. 
The intensity and nature of motor activity during the 
entire observation period did not differ from those of the 
control animals and were characterized by gradual inhi-
bition in accordance with age characteristics. No convul-
sions were observed in any animals. Neither the coordi-
nation of movements nor the skeletal muscle tone in the 
animals in the experimental groups were disturbed during 
the experiment, and did not differ from the corresponding 
indicators of the control animals.
The reaction to tactile, pain, sound and light stimuli 
was adequate in all the experimental animals; there were 
no differences between the experimental and control 
animals. The frequency and depth of respiratory move-
ments in the experimental animals were visually indis-
tinguishable from such in the animals from the control 
groups. 
When observing the condition of the hair, seasonal 
moulting of the animals was noted. The condition of the 
skin of experimental animals was not different from that 
in the control animals.
No failures of the sense organs were registered in any 
animal after the start of injecting the test substance. Du-
ring the administration of GMDP, the visible mucous 
membranes of the experimental animals, as well as of the 
control animals, remained pale pink in color; their humi-
dity did not change; there were no symptoms of bronchi-
tis, conjunctivitis and rhinitis.
The frequency of defecation and urination, the consis-
tency of fecal masses and urine color of the experimental 
and the control animals did not visually change after the 
administration of GMDP.
No visual deviations in feed and water intake by the 
animals were observed.
During the course of the study, animal mortality as-
sociated with natural age-related changes was observed. 
Mortality was observed in the males to a higher degree 
than in the females (Figs 1-8).
Taking into account the dynamics of the lethality of the 
rats, it was decided to discontinue the study, to conduct 
necropsy followed by a histological examination of the 
organs and tissues of the rats that survived the intragastric 
administration of GMDP within 21 months.
Thus, by the time the study was completed, depending 
on the dose received, from 96% to 54% of male and from 
96% to 78% of female mice, and from 0% to 4% of male 
and from 0% to 12% of female rats survived. No tumor 
formation was observed (Tables 1, 2).
Figure 1. The dynamics of lethality in the group of control mice Figure 2. The dynamics of lethality in the group of mice treated 
with GMDP at a dose of 0.186 mg/kg
Figure 3. The dynamics of lethality in the group of mice treated 
with GMDP at a dose of 1.86 mg/kg
Figure 4. The dynamics of lethality in the group of mice treated 
with GMDP at a dose of 6.13 mg/kg
Gudyrev OS et al.: The results of  the study of  the carcinogenic properties of  ...100
The body mass indicators of mice and rats, observed 
with the administration of GMDP at the doses studied, are 
given in Tables 3 and 4, respectively.
In the majority of the experimental animals during the 
experiment, up to the 427th day of observation in mice and 
up to the 489th day of observation in rats, there were no sta-
tistically significant differences in body weight indicators 
from those in the control groups; there were single cases 
of significant differences in body mass indicators in the 
control groups, both in terms of decreasing and increasing, 
without any signs of regularity. These observations can be 
explained by the individual characteristics of the animals.
Figure 5. The dynamics of lethality in the group of control rats Figure 6. The dynamics of lethality in the group of rats treated 
with GMDP at a dose of 0.086 mg/kg
Figure 7. The dynamics of lethality in the group of rats treated 
with GMDP at a dose of 0.86 mg/kg
Figure 8. The dynamics of lethality in the group of rats treated 
with GMDP at a dose of 2.83 mg/kg
Table 1. The Number of Mice Which Survived by the End of the Study
Dose Males Females
Number of live ani-
mals
Timing of detecting 
tumors
Number of live 
animals
Timing of detecting 
tumors
Control 47 (94%) Not found 48 (96%) Not found
0.186 mg/kg 48 (96%) Not found 46 (92%) Not found
1.86 mg/kg 34 (68%) Not found 44 (88%) Not found
6.13 mg/kg 27 (54%) Not found 39 (78%) Not found
Table 2. The Number of Rats Which Survived by the End of the Study
Dose Males Females
Number of live ani-
mals
Timing of detecting 
tumors
Number of live 
animals
Timing of detecting 
tumors
Control 2 (4%) Not found 2 (4%) Not found
0.086 mg/kg 2 (4%) Not found 6 (12%) Not found
0.86 mg/kg 0 (0%) Not found 4 (8%) Not found
2.83 mg/kg 1 (2%) Not found 0 (0%) Not found
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Table 3. The Results of the Study of the Body Weight of Mice During the Study of the Carcinogenic Properties of GMDP
Group Observation Day
1 8 15 22 29 36 43
Males
control
M 17.08 18 19.42 20.66 21.66 22.46 23.54
m 0.12 0.11 0.17 0.16 0.15 0.15 0.16
Males
0.186 mg/kg
M 16.86 18.06 19.62 20.44 21.2 22.76 23.4
m 0.13 0.12 0.16 0.17 0.15 0.17 0.15
р 0.208 0.709 0.398 0.345 0.033 0.192 0.526
Males
1.86 mg/kg
M 17.12 17.96 19.6 20.56 21.58 22.44 23.6
m 0.11 0.11 0.15 0.16 0.16 0.15 0.15
р 0.803 0.795 0.422 0.657 0.718 0.925 0.784
Males
6.13 mg/kg
M 17.1 18.04 19.72 20.68 21.46 22.2 23.62
m 0.12 0.11 0.15 0.17 0.15 0.15 0.15
р 0.905 0.799 0.189 0.932 0.355 0.232 0.719
Females control M 17 18.18 19.12 20.52 21.36 22.52 23.52
m 0.11 0.12 0.15 0.15 0.15 0.15 0.15
Females
0.186 mg/kg
M 16.8 17.96 19.66 20.62 21.58 22.5 23.88
m 0.11 0.12 0.16 0.17 0.16 0.14 0.15
р 0.219 0.194 0.015 0.668 0.314 0.923 0.092
Females
1.86 mg/kg
M 17.02 17.74 19.58 20.6 21.62 22.38 23.32
m 0.12 0.12 0.16 0.16 0.16 0.17 0.16
р 0.903 0.01 0.04 0.721 0.23 0.532 0.363
Females
6.13 mg/kg
M 17.04 18.16 19.52 20.22 21.84 22.32 23.46
m 0.12 0.12 0.15 0.16 0.15 0.16 0.17
р 0.808 0.905 0.064 0.184 0.027 0.359 0.789
50 57 64 78 92 108 124
Males
control
M 24.64 25.52 26.32 29.92 32.14 34.98 37.76
m 0.15 0.16 0.15 0.2 0.26 0.26 0.26
Males
0.186 mg/kg
M 24.3 25.36 26.52 29.84 32.4 34.32 37.3
m 0.17 0.17 0.15 0.23 0.26 0.26 0.24
р 0.134 0.495 0.351 0.795 0.478 0.074 0.193
Males
1.86 mg/kg
M 24.48 25.38 26.66 29.8 32.18 34.5 37.64
m 0.16 0.16 0.16 0.21 0.24 0.23 0.26
р 0.46 0.542 0.128 0.68 0.91 0.167 0.742
Males
6.13 mg/kg
M 24.4 25.52 26.92 29.88 32.3 34.7 37.72
m 0.16 0.15 0.16 0.21 0.24 0.24 0.26
р 0.272 1 0.007 0.891 0.655 0.428 0.913
Females control M 24.56 25.74 26.14 30 32.7 34.22 37.4
m 0.17 0.16 0.14 0.23 0.27 0.25 0.27
Females
0.186 mg/kg
M 24.38 25.58 26.44 30.02 32.48 34.32 37.94
m 0.17 0.16 0.17 0.22 0.24 0.23 0.24
р 0.447 0.485 0.179 0.949 0.542 0.772 0.141
Females
1.86 mg/kg
M 24.4 25.76 26.52 29.84 32.62 34.8 37.66
m 0.16 0.17 0.15 0.2 0.23 0.25 0.24
р 0.496 0.931 0.069 0.598 0.82 0.105 0.474
Females
6.13 mg/kg
M 24.36 25.36 26.72 29.84 32.68 34.64 37.94
m 0.15 0.17 0.17 0.22 0.23 0.25 0.24
р 0.38 0.111 0.011 0.614 0.955 0.238 0.135
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Group Observation Day
154 185 215 246 277 305 336
Males
control
M 39.84 36.92 33.98 31.12 31.48 31.18 32.2
m 0.25 0.3 0.35 0.38 0.33 0.31 0.31
Males
0.186 mg/kg
M 39.5 36.74 33.7 30.84 30.92 31.28 31.3
m 0.29 0.3 0.4 0.37 0.33 0.37 0.38
р 0.378 0.672 0.599 0.599 0.238 0.836 0.069
Males
1.86 mg/kg
M 39.5 37.5 33.7 29.98 30.78 31.18 31.5
m 0.25 0.32 0.35 0.33 0.37 0.39 0.36
р 0.341 0.185 0.574 0.027 0.165 1 0.142
Males
6.13 mg/kg
M 39.36 37.06 33.58 29.28 31.54 31.26 31.3
m 0.25 0.33 0.37 0.32 0.34 0.35 0.37
р 0.179 0.756 0.432 0 0.9 0.863 0.065
Females control M 39.56 34.72 31.02 28.2 26.22 25.72 26.52
m 0.24 0.35 0.33 0.41 0.5 0.5 0.55
Females
0.186 mg/kg
M 39.82 34 30.6 27.54 26.48 25.88 26.44
m 0.23 0.31 0.38 0.42 0.53 0.55 0.49
р 0.433 0.126 0.402 0.265 0.722 0.83 0.913
Females
1.86 mg/kg
M 39.98 34.34 30.88 27.56 26.7 26.24 26.9
m 0.24 0.33 0.36 0.42 0.52 0.51 0.52
р 0.218 0.426 0.773 0.281 0.504 0.468 0.617
Females
6.13 mg/kg
M 39.38 34.54 31.84 27.24 26.26 25.98 26.56
m 0.22 0.34 0.31 0.37 0.58 0.55 0.55
р 0.579 0.711 0.073 0.088 0.958 0.727 0.959
366 397 427 458 489 519 550
Males
control
M 32.44 32.32 32.1 32.2 32.04 31.69 32.17
m 0.34 0.36 0.34 0.45 0.41 0.31 0.46
Males
0.186 mg/kg
M 31.88 31.5 31.9 32.28 32.38 32.69 31.67
m 0.38 0.34 0.35 0.55 0.46 0.4 0.67
р 0.277 0.1 0.684 0.911 0.582 0.051 0.537
Males
1.86 mg/kg
M 31.96 32.32 31.86 29.48 26.2 25.5 24.74
m 0.37 0.38 0.38 0.47 0.61 0.51 0.98
р 0.344 1 0.638 0 0 0 0
Males
6.13 mg/kg
M 31.88 32 31.78 29.82 26.63 24.79 23.67
m 0.4 0.37 0.36 0.47 0.56 0.38 0.92
р 0.294 0.533 0.518 0 0 0 0
Females control M 26.78 26.56 25.76 26.96 28.46 28.82 28.92
m 0.55 0.61 0.49 0.64 0.71 0.47 0.58
Females
0.186 mg/kg
M 26.82 25.4 25.98 28.48 28.96 29.98 29.02
m 0.52 0.5 0.52 0.55 0.65 0.43 0.6
р 0.958 0.146 0.76 0.075 0.604 0.07 0.9
Females
1.86 mg/kg
M 25.9 25.94 25.86 25.86 26.26 26.11 24.84
m 0.55 0.53 0.56 0.51 0.48 0.41 0.41
р 0.262 0.443 0.893 0.181 0.012 0 0
Females
6.13 mg/kg
M 26.42 25.98 26.62 25.84 23.91 22.97 25.13
m 0.53 0.55 0.52 0.61 0.82 0.78 0.97
р 0.64 0.481 0.232 0.207 0 0 0.001
Note: M – the arithmetic average; m – the standard error; p – the level of statistical significance in comparison with the control
Table 3. Continued
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Table 4. The Results of the Study of the Body Weight of Rats During the Study of the Carcinogenic Properties of GMDP
Group Observation Day
1 8 15 22 29 36 43 50
Males
control
M 174.68 176.3 177.38 179.8 182.48 185.46 187.56 190.28
m 0.41 0.33 0.26 0.3 0.24 0.29 0.25 0.25
Males
0.086 mg/kg
M 174.92 176.56 177.78 180.12 182.22 185.1 187.26 189.78
m 0.47 0.35 0.24 0.3 0.23 0.29 0.25 0.3
р 0.703 0.589 0.259 0.451 0.433 0.388 0.395 0.206
Males
0.86 mg/kg
M 175.86 176.16 177.56 179.86 182.36 185 187.38 189.94
m 0.45 0.38 0.23 0.28 0.26 0.31 0.25 0.3
р 0.057 0.782 0.606 0.884 0.736 0.281 0.606 0.388
Males
2.83 mg/kg
M 175.3 176.18 177.58 179.92 183 185.7 187.38 187.62
m 0.42 0.36 0.26 0.28 0.22 0.29 0.25 0.26
р 0.294 0.805 0.587 0.77 0.113 0.559 0.608 0
Females control M 164.5 165.72 167.68 170.12 172.42 175.26 177.48 180.26
m 0.45 0.38 0.26 0.26 0.24 0.3 0.22 0.28
Females
0.086 mg/kg
M 165.3 165.88 167.22 170.08 172.5 174.88 177.38 180.2
m 0.42 0.36 0.24 0.28 0.25 0.26 0.23 0.3
р 0.201 0.762 0.199 0.917 0.815 0.343 0.756 0.884
Females
0.86 mg/kg
M 164.72 166.34 167.58 170.46 172.52 174.98 177.32 179.96
m 0.45 0.33 0.24 0.27 0.24 0.3 0.25 0.26
р 0.732 0.224 0.78 0.365 0.768 0.509 0.629 0.439
Females
2.83 mg/kg
M 165.32 165.7 167.28 170.18 172.14 174.48 177.62 180.34
m 0.4 0.37 0.26 0.28 0.23 0.28 0.21 0.28
р 0.176 0.97 0.278 0.875 0.399 0.063 0.645 0.84
57 64 78 92 108 124 154 185
Males
control
M 192.44 195.06 200.36 211.46 219.92 227.82 235.22 232.48
m 0.27 0.26 0.43 0.33 0.45 0.6 0.46 0.76
Males
0.086 mg/kg
M 192.38 194.94 199.56 210.54 220.04 228.02 234.68 233.8
m 0.23 0.28 0.45 0.37 0.47 0.63 0.45 0.73
р 0.864 0.755 0.201 0.066 0.854 0.819 0.405 0.213
Males
0.86 mg/kg
M 192.42 195.02 200.3 210.74 219.96 227.74 234.64 233.34
m 0.26 0.25 0.51 0.35 0.41 0.71 0.45 0.76
р 0.957 0.912 0.928 0.142 0.948 0.931 0.371 0.428
Males
2.83 mg/kg
M 187.34 192.26 200.9 211.08 220.42 228.12 235.7 233.92
m 0.25 0.22 0.42 0.32 0.46 0.7 0.48 0.84
р 0 0 0.369 0.414 0.44 0.745 0.476 0.208
Females control M 182.14 185.08 190.74 201.1 211.14 220.78 228.46 230.1
m 0.24 0.27 0.4 0.49 0.49 0.52 0.33 0.41
Females
0.086 mg/kg
M 182.56 185.32 189.56 200.3 210.58 221.38 229.3 230.72
m 0.23 0.25 0.44 0.53 0.48 0.51 0.37 0.38
р 0.206 0.522 0.049 0.272 0.417 0.412 0.091 0.273
Females
0.86 mg/kg
M 182.44 185.28 190.08 201.66 211.4 220.5 228.96 230.7
m 0.26 0.29 0.4 0.58 0.46 0.52 0.36 0.43
р 0.39 0.62 0.248 0.464 0.7 0.705 0.308 0.319
Females
2.83 mg/kg
M 182.06 185.6 189.72 201.52 210.6 221.16 228.68 229.68
m 0.24 0.3 0.42 0.54 0.44 0.51 0.35 0.4
р 0.813 0.207 0.081 0.566 0.413 0.604 0.646 0.465
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Group Observation Day
215 246 277 305 336 366 397 427
Males
control
M 233.48 235.98 236.1 235.84 236.14 235.86 234.7 235.42
m 0.63 0.62 0.55 0.64 0.65 0.64 0.59 0.7
Males
0.086 mg/kg
M 233.6 235.06 236.08 236.26 236.6 235.08 235.96 235.9
m 0.67 0.66 0.56 0.57 0.54 0.69 0.71 0.63
р 0.896 0.31 0.98 0.624 0.588 0.411 0.174 0.611
Males
0.86 mg/kg
M 233.88 234.7 235.44 235.18 235.64 235.22 235.52 234.76
m 0.62 0.66 0.55 0.59 0.55 0.72 0.66 0.69
р 0.651 0.158 0.395 0.449 0.561 0.51 0.356 0.503
Males
2.83 mg/kg
M 233.2 234.9 235.46 234.64 236.26 235.66 236 235.46
m 0.63 0.68 0.55 0.57 0.53 0.71 0.6 0.67
р 0.753 0.24 0.409 0.162 0.887 0.836 0.125 0.967
Females control M 230.66 231.4 231.48 232.78 232.74 232.92 232.02 233.38
m 0.52 0.67 0.68 0.64 0.67 0.66 0.62 0.68
Females
0.086 mg/kg
M 230.1 231.36 230.46 232.06 231.4 232.9 232.7 232.44
m 0.54 0.67 0.52 0.71 0.66 0.69 0.63 0.62
р 0.46 0.967 0.235 0.454 0.157 0.983 0.441 0.31
Females
0.86 mg/kg
M 231.56 232.52 232.66 231.28 232.34 231.18 232.98 232.84
m 0.47 0.6 0.69 0.56 0.62 0.73 0.6 0.61
р 0.206 0.216 0.224 0.081 0.662 0.08 0.268 0.556
Females
2.83 mg/kg
M 230.1 231.94 231.74 231.06 231.9 232.44 230.94 231.56
m 0.54 0.69 0.72 0.63 0.58 0.66 0.63 0.66
р 0.46 0.577 0.792 0.059 0.342 0.608 0.223 0.059
458 489 519 550 580 611 642
Males
control
M 233.72 235 262.92 268.1 255.2 248.67 239
m 0.99 1.53 9.4 9.4 13.59 19.47 19
Males
0.086 mg/kg
M 236.53 233.89 226.44 234 233.25 251 243
m 1.73 3.34 7.37 8.99 9.16 3.42 3
р 0.166 0.78 0.004 0.017 0.191 0.895 0.855
Males
0.86 mg/kg
M 234.97 231.1 237.5 260 – – –
m 2.17 4.26 12.45 – – – –
р 0.573 0.337 0.189 – – – –
Males
2.83 mg/kg
M 233.22 236.14 219.67 248 254 248 240
m 2.04 4.29 14.75 20 – – –
р 0.817 0.782 0.021 0.401 – – –
Females control M 234.17 233.5 230.46 216 215.09 209.67 221
m 1.51 3.26 6.02 7.26 7.7 10.06 7
Females
0.086 mg/kg
M 234.31 234.4 227.8 207.68 212.89 223.09 211
m 1.39 2.31 4.25 7.87 8.42 9.06 6.49
р 0.946 0.82 0.714 0.455 0.86 0.366 0.447
Females
0.86 mg/kg
M 236.6 236.14 224.62 216.67 228.17 228.5 229.5
m 1.77 2.66 5.27 5.02 4.63 3.72 3.1
р 0.298 0.539 0.468 0.941 0.153 0.074 0.25
Females
2.83 mg/kg
M 235.74 238 220 220 242 243 –
m 2.03 2.7 7.86 11.12 6.98 11 –
р 0.526 0.343 0.36 0.774 0.07 0.131 –
Note: M – the arithmetic average; m – the standard error; p – the level of statistical significance in comparison with the control
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At the same time, in the subsequent observation pe-
riod, in the mice treated with GMDP at doses of 1.86 
mg/kg and 6.13 mg/kg, as well as in male rats treated 
with GMDP at doses of 0.086 mg/kg and 2.83 mg/kg, 
a statistically significant lag in body mass indexes from 
those in the corresponding control groups was observed, 
progressing towards the end of the study. At the same 
time, in the other groups of the experimental animals, in 
spite of the existing mortality, there were no statistically 
significant lags in body weight indexes from those in the 
control groups.
In accordance with the research plan, necropsy of the 
bodies of the dead animals and a macroscopic study of 
their internal organs for tumors were carried out. In addi-
tion, a routine necropsy was carried out on the bodies of 
all the surviving mice and rats that had received the test 
drug for 18 and 21 months, respectively, and the organs 
and tissues were recovered for subsequent histological 
examination.
No visual differences between the experimental groups 
of animals and the control animals were observed. Neit-
her were any tumors detected. The overall macroscopic 
pattern was as follows.
Oral cavity. No pathological contents observed.
Tongue. Clean, regular shape, soft texture, pale color.
Esophagus. The mucosa of the esophagus was pale 
gray, smooth, shiny, with patent lumen.
Stomach. The stomach with well pronounced folds 
of the mucous membrane, the mucosa of pale gray color, 
moist, shiny, no pathological contents observed.
Pancreas. Pancreas in its typical location, pale gray in 
color, dense, fine granular in section.
Liver. The liver is dense, with a smooth surface, the 
lobes are pronounced, pale brown in section, anemic.
Large and small intestines. The contents of the in-
testines are adequate to each of their parts, the mucous 
membrane with definite folds, moist, pale gray in color, 
with patent lumen, no pathological contents observed.
Mucous membranes of larynx, trachea, main bron-
chi. Pale pink, smooth, moist, shiny, with patent lumen, 
no pathological contents observed.
Heart. The heart is rounded, well contracted. Under 
the epicardium – the usual venous pattern of the coronary 
vessels. The valve leaflets are thin, translucent. Endocar-
dium is smooth and shiny.
Aorta. Elastic, smooth and clean intima, with patent 
lumen.
Kidneys. The kidney capsule strips easily; there is a 
smooth surface under it; in section – the kidneys have 
weak blood filling, with a clear lamellar structure; the 
mucous membranes of the pelvises and tje bladder are pale 
gray, moist, shiny, no pathological contents observed. 
Adrenal glands. The adrenal glands are rounded, with 
the parenchyma clearly divided into the cortex and me-
dulla, pale gray, not adhered to the surrounding tissues.
Spleen. The spleen in its typical location, with a 
smooth capsule, n section – of gray-red color; the splenic 
pulp does not scrape away.
Brain. The brain membranes are translucent, smooth, 
and shiny. The convolutions of the brain are well outlined. 
In section, the substance of the brain is wet, shiny, with 
a symmetrical pattern of the structure. The vessels of the 
base of the brain are arranged symmetrically, with collap-
sed walls.
Organs of the thoracic and abdominal cavities are 
located properly. The cavities are free from liquids and 
adhesions.
Lungs. The collapsed lungs, the lobes are distinguis-
hable, pale gray in color, covered with thin pleura, with 
weak blood filling, no pathological contents observed.
Thymus. Thymus is bilobate, leaf-shaped, well identi-
fied among the organs of the anterior mediastinum. Tissue 
is elastic, homogeneous, pale gray.
Thyroid. Thyroid gland is reddish-pale, of normal size 
and shape, with moderately dense texture.
Testes and epididymises (in males). Testes and epi-
didymises are of usual form, elastic consistency, and pale 
gray color. In secion, layers are visualized in the tesis 
tissue.
Ovaries (in females). Ovaries are gray-pink, with 
elastic consistency, surrounded with a small amount of 
adipose tissue. In section, follicles can be identified in 
the tissue.
Uterus (in females). Uterus septus, dense, with smooth 
surface; the color is pale yellowish-pink. The cavity is 
without pathological contents. The horns are thin, long, 
passable, with no pathological content observed.
The following organs and tissues of mice and rats that 
had received the test drug for 18 and 21 months were sub-
jected to histological examination, respectively: stomach, 
small intestinal fragment, large intestinal fragment, liver, 
spleen, kidney, adrenal gland, bladder, brain, lung, heart, 
testis (in males), uterus and ovary (in females).
The study did not reveal any intergroup differences in 
the histological picture of the studied organs in the expe-
rimental animals in comparison with the control.
Conclusion
Thus, intragastric administration of GMDP (Licopid®) 
produced by Peptek JSC, Russia, to male and female mice 
for 18 months at doses of 0.186 mg/kg, 1.86 mg/kg and 
6.13 mg/kg and to rats for 21 months at doses of 0.086 
mg/kg, 0.86 mg/kg and 2.83 mg/kg does not lead to tumor 
formation in the experimental animals.
Given the fact that the excipients that make up Lico-
pid® are traditional, well-studied additive agents that do 
not have carcinogenic activity, basing on the results ob-
tained, it can be concluded that there are no carcinogenic 
properties in the finished pharmaceutical form of GMDP 
– Licopid®. 
The obtained results expand knowledge about safety, 
in particular, carcinogenicity in long-term in-vivo expe-
riments, of the active pharmaceutical substance GMDP 
and drug Licopid® manufactured by Peptek JSC, Russia.
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